✦ LIBER ✦

Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom*

✍ Scribed by A. Davies; S. Ridley; J. Hutton; C. Chinn; B. Barber; D. C. Angus

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluating the use of Drotrecogin alfa (

✍ Salmaan Kanji; Marc M. Perreault; Clarence Chant; David Williamson; Lisa Burry 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 199 KB

Treatment effects of drotrecogin alfa (a

✍ J.-F. Dhainaut; S. B. Yan; D. E. Joyce; V. Pettilä; B. Basson; J. T. Brandt; D. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB

How many patients with severe sepsis are

✍ Andre C. Kalil; Junfeng Sun 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 223 KB

Cost effectiveness of recombinant activa

✍ S. Morris; S. Ridley; V. Munro; M. C. Christensen; the NovoSeven® Trauma Study G 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 527 KB

Use of Drotrecogin alfa (activated) in I

✍ Guido Bertolini; Carlotta Rossi; Abramo Anghileri; Sergio Livigni; Antonio Addis 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 262 KB

Cost-effectiveness of the Surviving Seps

✍ David Suarez; Ricard Ferrer; Antonio Artigas; Izaskun Azkarate; José Garnacho-Mo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 396 KB